loader
Please Wait
Applying Filters...

Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Tofacitinib Citrate, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Tofacitinib Citrate

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    2D Structure
    Also known as: 540737-29-9, Tasocitinib citrate, Xeljanz, Cp-690550 citrate, Tofacitinib (citrate), Tofacitinib (cp-690550) citrate
    Molecular Formula
    C22H28N6O8
    Molecular Weight
    504.5  g/mol
    InChI Key
    SYIKUFDOYJFGBQ-YLAFAASESA-N
    FDA UNII
    O1FF4DIV0D
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    2-hydroxypropane-1,2,3-tricarboxylic acid;3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile
    2.1.2 InChI
    InChI=1S/C16H20N6O.C6H8O7/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16;7-3(8)1-6(13,5(11)12)2-4(9)10/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t11-,13+;/m1./s1
    2.1.3 InChI Key
    SYIKUFDOYJFGBQ-YLAFAASESA-N
    2.1.4 Canonical SMILES
    CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
    2.1.5 Isomeric SMILES
    C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
    2.2 Other Identifiers
    2.2.1 UNII
    O1FF4DIV0D
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Cp 690,550

    2. Cp 690550

    3. Cp-690,550

    4. Cp-690550

    5. Cp690550

    6. Tasocitinib

    7. Tofacitinib

    8. Xeljanz

    2.3.2 Depositor-Supplied Synonyms

    1. 540737-29-9

    2. Tasocitinib Citrate

    3. Xeljanz

    4. Cp-690550 Citrate

    5. Tofacitinib (citrate)

    6. Tofacitinib (cp-690550) Citrate

    7. Xeljanz Xr

    8. Tofacitinib Citrate [usan]

    9. Cp-690,550-10

    10. Tasocitinib Monocitrate

    11. 540737-29-9 (citrate)

    12. Cp-690550-10

    13. Cp 690550 Citrate

    14. O1ff4div0d

    15. 3-((3r,4r)-4-methyl-3-(methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate

    16. Chebi:71197

    17. 1-piperidinepropanenitrile, 4-methyl-3-(methyl-7h-pyrrolo(2,3-d)pyrimidin-4-ylamino)- Beta-oxo-, (3r,4r)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)

    18. 2-hydroxypropane-1,2,3-tricarboxylic Acid; 3-[(3r,4r)-4-methyl-3-[methyl({7h-pyrrolo[2,3-d]pyrimidin-4-yl})amino]piperidin-1-yl]-3-oxopropanenitrile

    19. 2-hydroxypropane-1,2,3-tricarboxylic Acid;3-[(3r,4r)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile

    20. Unii-o1ff4div0d

    21. Mfcd11616529

    22. 3-{(3r,4r)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate

    23. 3-{(3r,4r)-4-methyl-3-[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile Citrate Salt

    24. 3-{(3r,4r)-4-methyl-3-[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl}-amino]-piperidin-1-yl)-3-oxo-propionitrile Citrate Salt

    25. Xeljanz (tn)

    26. Tofacitinib Monocitrate

    27. Tasocitinib Citric Acid Salt

    28. Cep-18770(delanzomib)

    29. Mls006010058

    30. Schembl1374185

    31. Chembl2103743

    32. Tofacitinib Citrate (jan/usan)

    33. Amy4175

    34. Dtxsid80202404

    35. Ex-a204

    36. Tofacitinib Citrate [jan]

    37. C16h20n6o.c6h8o7

    38. Tofacitinib Monocitrate [mi]

    39. Hy-40354a

    40. S5001

    41. Tofacitinib Citrate [who-dd]

    42. Akos022178222

    43. Cp-690550 - Tofacitinib Citrate

    44. Tofacitinib Citrate, >=98% (hplc)

    45. Ccg-269730

    46. Cs-0928

    47. Tofacitinib Citrate [orange Book]

    48. Ac-25004

    49. As-19392

    50. Bt163661

    51. Smr004701220

    52. Cp-690550 Citrate (tofacitinib Citrate)

    53. Tofacitinib Citrate (cp-690550 Citrate)

    54. Cp 690550-10

    55. D09783

    56. Q27139435

    57. (3r,4r)-4-methyl-3-(methyl-7h-pyrro Lo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepro Panenitrile Citrate

    58. (3r,4r)-4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-?-oxo-1-piperidinepropanenitrile Citrate

    59. (3r,4r)-4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidine Propanenitrile 2-hydroxy-1,2,3-propanetricarboxylate

    60. (3r,4r)-4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-ss-oxo-1-piperidinepropanenitrile Citrate Salt

    61. 1-piperidinepropanenitrile, 4-methyl-3-(methyl-7h-pyrrolo(2,3-d)pyrimidin-4-ylamino)-.beta.-oxo-, (3r,4r)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)

    62. 1-piperidinepropanenitrile,4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-,(3r,4r)-,2-hydroxy-1,2,3-propanetricarboxylate(1:1)

    63. 3-((3r,4r)-4-methyl-3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxo-propanenitrile2-hydroxypropane-1,2,3-tricarboxylate (1:1)

    64. 3-((3r,4r)-4-methyl-3-(methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile Mono Citrate Salt

    65. 3-{(3r,4r)-4-methyl-3-[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile Mono Citrate Salt

    2.4 Create Date
    2006-10-25
    3 Chemical and Physical Properties
    Molecular Weight 504.5 g/mol
    Molecular Formula C22H28N6O8
    Hydrogen Bond Donor Count5
    Hydrogen Bond Acceptor Count12
    Rotatable Bond Count8
    Exact Mass504.19686187 g/mol
    Monoisotopic Mass504.19686187 g/mol
    Topological Polar Surface Area221 Ų
    Heavy Atom Count36
    Formal Charge0
    Complexity716
    Isotope Atom Count0
    Defined Atom Stereocenter Count2
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 2  
    Drug NameXeljanz
    PubMed HealthTofacitinib (By mouth)
    Drug ClassesAntirheumatic, Musculoskeletal Agent
    Drug LabelXELJANZ is the citrate salt of tofacitinib, a JAK inhibitor.Tofacitinib citrate is a white to off-white powder with the following chemical name: (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo [2,3-d]pyrimidin-4-ylamino)--oxo-1-piperidinepropanenitrile, 2-hy...
    Active IngredientTofacitinib citrate
    Dosage FormTablet
    RouteOral
    Strengtheq 5mg base
    Market StatusPrescription
    CompanyPf Prism Cv

    2 of 2  
    Drug NameXeljanz
    PubMed HealthTofacitinib (By mouth)
    Drug ClassesAntirheumatic, Musculoskeletal Agent
    Drug LabelXELJANZ is the citrate salt of tofacitinib, a JAK inhibitor.Tofacitinib citrate is a white to off-white powder with the following chemical name: (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo [2,3-d]pyrimidin-4-ylamino)--oxo-1-piperidinepropanenitrile, 2-hy...
    Active IngredientTofacitinib citrate
    Dosage FormTablet
    RouteOral
    Strengtheq 5mg base
    Market StatusPrescription
    CompanyPf Prism Cv

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Janus Kinase Inhibitors

    Agents that inhibit JANUS KINASES. (See all compounds classified as Janus Kinase Inhibitors.)

    Post Enquiry
    POST ENQUIRY